LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.

LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.

LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) --  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.

$10M milestone payment from Merck triggered Agenus is eligible for up to an additional $85 million in milestones plus royalties on sales LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies,

AGEN1181 : New clinical responses and intratumoral Treg depletion AGEN 1777 ( TIGIT ) is Fc enhanced for optimized immune performance & broader benefit AGEN2373 (anti-CD137) : Clinical benefit with no liver toxicity Allogeneic iNKTs : Potent tumor cell killing and tumor microenvironment regulation

Immunotherapy Pioneer to Join As Company Ramps Up Commercialization and NextGen Clinical Pipeline Efforts LEXINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and

Allogeneic (off the shelf) iNKT cell therapy targets patients with moderate to severe COVID-19 iNKT cells designed to clear SARS-CoV-2 virus while reducing harmful inflammation LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an

Balstilimab rolling BLA filing and FDA review underway COVID-19 trial open with patients in screening for iNKT Cell Therapy New data and clinical responses with AGEN1181 to be presented at SITC on NOV11 LEXINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agenus Inc.

Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate